CONFERENCE UPDATE: WCLC 2020
Osimertinib significantly improved disease-free survival in patients with resected EGFR-mutated non-small cell lung cancer, regardless of adjuvant chemotherapy use
Association of AL with neurological effects in the pediatric population
A retrospective study on a pediatric population has shown that neurologic manifestations (NMs) in patients with acute leukemia (AL), relating to a greater mortality rate.1 AL is the most prevalent childhood cancer, which accounts for one-third of all cancers within the age range.1 Although the survi
Favorability of sequential conditioning over intensive remission induction chemotherapy prior to allo-HCT
In the 64th American Society of Hematology (ASH) Annual Meeting and Exposition 2022, Dr. Johannes Schetelig, on behalf of the Study Alliance Leukemia and the German Cooperative Transplant Study Group, presented his group’s study to prove their hypothesis that salvage chemotherapy before allogeneic h
Administration of ANTI-PD1 antibody pembrolizumab improves EFS in tnbc patients
Among different subtypes of breast cancer, triple-negative breast cancer (TNBC) is associated with the least overall survival (OS).1 The use of immune checkpoint inhibitors, such as programmed death 1 (PD1) or programmed death-ligand 1 (PD-L1), benefits TNBC patients.1 An interim analysis of a phase 3 trial revealed that administration of pembrolizumab, an immune checkpoint inhibitor, along with neoadjuvant chemotherapy, resulted in a pathological complete response in a significant number of patients with high-risk early TNBC.1
Adopting durvalumab consolidation therapy: A breakthough for non-small cell lung cancer treatment
Despite recent advances in oncology, drug resistance and disease relapse have remained a significant unmet need among non-small cell lung cancer (NSCLC). Recently, the development of novel therapeutics including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have made multiple breakthroughs in the treatment of NSCLC. In a virtual meeting and clinical debate, “Durvalumab in EGFRm Stage III NSCLC – To Offer or Not to Offer?”, Dr. Victor Lee summarized the key studies of NSCLC treatments, including the phase 3 PACIFIC trial of an anti-programmed cell death receptor ligand 1 (PD-L1) drug, durvalumab. Dr. Oscar Chan and Dr. Jonathan Nyaw then discussed the applications and other considerations of the durvalumab regimen among stage 3 Epidermal Growth Factor Receptor mutated (EGFRm) NSCLC patients in the clinical setting.
A milestone in biomarker testing and therapies for lung cancer
With advancement in biomarker-driven treatment and targeted therapies for lung cancer, novel strategies are employed to optimize personalized regimens for different subtypes of lung cancer.1 To keep track of the evolving lung cancer management, a symposium regarding biomarker and treatment landscape for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) was held at the World Conference on Lung Cancer 2021.1
Combination of durvalumab, tremelimumab and chemotherapy as a potential new first-line mNSCLC treatment option
Immunotherapies targeting the programmed death protein 1 (PD-1)/programmed death-ligand1 (PD-L1) pathway, either administered as a monotherapy or in combination with chemotherapy, have transformed the lung cancer treatment.' While the inclusion of chemotherapy to anti-PD-L1 may provide early disease control, adding anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) to anti- PD-L1 with or without chemotherapy may confer long-term survival benefits for some patients. 1
POSEIDON is a randomized, open label, multicenter phase 3 study evaluating durvalumab with and without tremelimumab in combination with chemotherapy regimens as first-line treatment for squamous or non-squamous metastatic non-small cell lung cancer (mNSCLC).' The eligible patients with metastatic non-small cell lung cancer (mNSCLC) received a combined regimen of durvalumab, tremelimumab, and chemotherapy. Progression-free survival significantly improved for patients receiving durvalumab plus chemotherapy compared with chemotherapy alone, with a positive trend for overall survival that did not reach statistical significance.'